Pediatric drug development: formulation considerations

References

• Directive 2001/20/EC of the European Parliament and the Council on the approximation of the law, regulations and administrative provisions of the member states relating to the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for human use. (2001). Available from: www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf [last accessed 10 May 2013]
   Google Scholar
• Rakhmanina NY, Van den Anker JN. Pharmacological research in paediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006;58:4–14
   PubMed Web of Science ®Google Scholar
• European Commission, Enterprise Directorate-General. “Consultation document on paediatrics ‘Better Medicines for Children – proposed regulatory actions on paediatric medicinal products”’; 2002; Brussels
   Google Scholar
• 105th U.S. Congress. “H.R.1411: Food and Drug Administration Regulatory Modernization Act of 1997”. U.S. House of Representative bill summary & status (in English); Library of Congress Thomas. Retrieved 23 March 2013
   Google Scholar
• Best Pharmaceuticals for Children Act (Public Law No:107-109); 2002. Available from: www.fda.gov/opacom/laws/pharmkids/pharmkids.html [last accessed 5 Apr 2013]
   Google Scholar
• European Medicines Agency. The European paediatric initiative: history of the paediatric regulation, (EMEA/17967/04 Rev 1); 2007. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf/ [last accessed 7 Apr 2013]
   Google Scholar
• European Medicines Agency. ICH Topic E11: note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99); 2001. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf/ [last accessed 7 Apr 2013]
   Google Scholar
• Paediatric Research Equity Act, (Public Law No: 108-155); 2003. Available from: www.fda.gov/cder/paediatric/S-650-PREA.pdf [last accessed 2 May 2013]
   Google Scholar
• Food and Drug Administration Amendments Act of 2007. Proceedings of 110th Congress of the United States of America; Washington, D.C., USA; 2007. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf/ [last accessed 31 Aug 2010]
   Google Scholar
• Commission of the European Communities Regulation (EC) No 1901/2006 on medicinal products for paediatric use and amending Regulation (EC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.(2006). Official Journal of the European Communities, L378 27/12/2006. 1–19.19
   Google Scholar
• Smyth RL, Edwards AD. A major new initiative to improve treatment for children. Arch Dis Child 2006;91:212–13
   PubMed Web of Science ®Google Scholar
• Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet 1980;5:485–527
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Rademaker CM, Schobben AF, Van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006;45:1077–97
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:447–71
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Moran C, Benjamin DK, Smith PB. Paediatric antifungal agents. Curr Opin Infect Dis 2009;22:553–8
   PubMed Web of Science ®Google Scholar
• McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:S23–9
   Google Scholar
• Rane A, Wilson JT. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet 1976;1:2–24
   PubMedGoogle Scholar
• Jalling B. Plasma and cerebrospinal fluid concentrations of phenobarbital in infants given single doses. Dev Med Child Neurol 1974;16:781–93
   PubMed Web of Science ®Google Scholar
• Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 1960;62:787–94
   Google Scholar
• Boucher FD, Modlin JF, Weller S, et al. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007;4:37–45
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Mimaki T, Cox S, et al. Phenytoin age-dose concentration relationship in children. Ther Drug Monit 1994;6:145–50
   Google Scholar
• Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part II. Clin Pharmacokinet 2002;41:1077–94
   PubMed Web of Science ®Google Scholar
• Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Paediatrics 1966;37:1005–7
   PubMed Web of Science ®Google Scholar
• Huang NN, High RN. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953;42:657–68
   PubMed Web of Science ®Google Scholar
• Silverio J, Poole JW. Serum concentrations of ampicillin in newborn infants after oral administration. Paediatrics 1973;51:578–80
   PubMed Web of Science ®Google Scholar
• O’Connor WJ, Warren GH, Edrada LS. Serum concentrations of sodium nafcillin in infants during the perinatal period. Antimicrob Agents Chemother 1965;5:220–2
   PubMedGoogle Scholar
• Jalling B. Plasma concentrations of phenobarbital in the treatment of seizures in newborns. Acta Paediatr Scand 1975;64:514–24
   PubMed Web of Science ®Google Scholar
• Signer E, Fridrich R. Gastric emptying in newborns and young infants. Acta Paediatr Scand 1975;64:525–30
   PubMed Web of Science ®Google Scholar
• Meissner HC, Smith AL. The current status of chloramphenicol. Paediatrics 1979;64:348–56
   PubMed Web of Science ®Google Scholar
• McCracken GH, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. Paediatrics 1978;62:738–43
   PubMed Web of Science ®Google Scholar
• Aulton, ME. Autlon’s pharmaceutics, the design and manufacture of medicines. 3rd ed. Churchill Livingstone; 2007: ISBN: 978-0443101083
   Google Scholar
• Thomson ABR, Shaffer EA. First principles of gastroenterology: the basis of disease and the approach to management. 5th ed. Janssen-Ortho; 2000: ISBN: 978-0920163184
   Google Scholar
• Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003;17:281–99
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157–67
   PubMed Web of Science ®Google Scholar
• Kurz H, Michels H, Stickel HH. Differences in the binding of drugs to plasma proteins from newborn and adult man. II. Eur J Clin Pharmacol 1977;11:469–72
   PubMed Web of Science ®Google Scholar
• Roberts RJ, ed. Pharmacologic principles in therapeutics in infants. In: Drug therapy in infants: pharmacologic principles and clinical experience. Philadelphia (PA): WB Saunders; 1984:3–12
   Google Scholar
• Driessen OHJ, Sorgedrager N, Michel MF, et al. Pharmacokinetic aspects of therapy with ampicillin and kanamycin in newborn infants. Eur J Clin Pharmacol 1978;13:449–57
   Web of Science ®Google Scholar
• American Academy of Paediatrics. Committee on Drugs. Alternative routes of drug administration – advantages and disadvantages (subject review). Paediatrics 1997;100:143–52
   PubMed Web of Science ®Google Scholar
• Silverman WA, Anderson DH, Blanc WA. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Paediatrics 1956;18:614–24
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002;53:390–2
   PubMed Web of Science ®Google Scholar
• Lowry JA, Jarrett RV, Wasserman G, et al. Theophylline toxicokinetics in premature newborns. Arch Pediatr Adolesc Med 2001;155:934–9
   PubMed Web of Science ®Google Scholar
• Rane A. Basic principles of drug disposition and action in infants and children. In: Yaffe JF, ed. Paediatric pharmacology: therapeutic principles in practice. New York: Grune & Stratton; 1980:7–28
   Google Scholar
• Kuhn R, Nahata MC, Powell DA. Netilmicin pharmacokinetics in newborn infants. Eur J Clin Pharmacol 1986;29:635–7
   PubMed Web of Science ®Google Scholar
• McNally GP, Railkar AM. Formulation of paediatric dosage forms. In: Mulberg AE, Silber SA, Anker VJN, eds. Paediatric drug development, concepts and applications. Hoboken (NJ): John Wiley and Sons, Inc.; 2009:553
   Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20
   PubMed Web of Science ®Google Scholar
• World Health Organization. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series, No. 937; 2006
   Google Scholar
• Thompson JE. A practical guide to contemporary pharmacy practice. Baltimore (MD): Williams & Wilkins; 1998
   Google Scholar
• Serrajuddin ATM, Mufson D. pH-solubility profiles of organic bases and their hydrochloride salts. Pharm Res 1985;2:65–8
   PubMedGoogle Scholar
• Rubino JT, Yalkowsky SH. Solubilization by cosolvents. Part 3. Diazepan and benzocaine in binary solvents. Buu Parenter Drug Assoc 1985;39:106–111
   Google Scholar
• Rubino JT, Yalkowsky SH. Cosolvency and deviations from log-linear solubilization. Pharm Res 1987;4:231–5
   PubMed Web of Science ®Google Scholar
• Rubino JT, Yalkowsky SH. Cosolvency and cosolvent polarity. Pharm Res 1987;4:220–30
   PubMed Web of Science ®Google Scholar
• Millard JW, Alvarez-Núñez FA, Yalkowsky SH. Solubilization by cosolvents, establishing useful constants for the log/linear model. Int J Pharm 2002;245:153–66
   PubMed Web of Science ®Google Scholar
• Kaneto U, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev 1998;98:2045–76
   PubMed Web of Science ®Google Scholar
• Agharkar S, Lindenbaum S, Higuchi T. Enhancement of solubility of drug salts by hydrophilic counter-ions: properties of organic salts of an anti-malarial drug. J Pharm Sci 1976;65:747–9
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Del Rev 2007;59:603–16
   PubMed Web of Science ®Google Scholar
• Chaumeil JC. Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol 1998;20:211–15
   PubMed Web of Science ®Google Scholar
• Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate paediatric management of the anti-HIV therapy. Curr HIV Res 2010;8:223–31
   PubMed Web of Science ®Google Scholar
• Alexander KS, Haribhakti RP, Parker GA. Stability of acetazolamide in suspension compounded from tablets. Am J Hosp Pharm 1991;48:1241–4
   PubMedGoogle Scholar
• Longer MA. Chemical stability of pharmaceuticals. New York: John Wiley; 1986:345–50
   Google Scholar
• Addicks W. Furosemide. In: Connors KA, Amidon GL, Stella VJ, eds. Chemical stability of pharmaceuticals. New York: John Wiley; 1986:474–7
   Google Scholar
• Breitkreuz J, Tuleu C, Solomonidou D. Paediatric formulations. In: Rose K, Van den Anker JN, eds. Guide to paediatric clinical research. Basel, Switzerland: S. Karger AG; 2007:65–77
   Google Scholar
• Florence AT, Attwood D, eds. Drug stability. In: Physicochemical principles of pharmacy. 4th ed. London: Pharmaceutical Press Publications division of the Royal Pharmaceutical Society of Great Britain; 2006:93–138
   Google Scholar
• Giam JA, McLachan AJ. Extemporaneous product use in paediatric patients: a systematic review. Int J Pharm Pract 2008;16:3–10
   Google Scholar
• Golightly LK, Smolinske SS, Bennett ML, et al. Pharmaceutical excipients. Adverse effects associated with ‘inactive’ ingredients in drug products. Med Toxicol 1988;3:128–65 (Part I) and 3:209–40 (Part II)
   Google Scholar
• Costello I, Long PF, Wong IK, et al. Paediatric drug handling. Cornwall: Pharmaceutical Press; 2007
   Google Scholar
• Nahata MC, Morosco RS. Stability of lisinopril in two liquid dosage forms. Ann Pharmacother 2004;38:396–9
   PubMed Web of Science ®Google Scholar
• Vignesh M, Sivakumar M, Parkavi V, et al. Stabilization of folic acid in liquid dosage form: formulation development, method validation and comparative analysis. Int J Pharm Chem Sci 2012;1:332–8
   Google Scholar
• Sosnowska K, Winnicka K, Czajkowska-Kośnik A. Stability of extemporaneous enalapril maleate suspensions for paediatric use prepared from commercially available tablets. Acta Pol Pharm 2009;66:321–6
   PubMed Web of Science ®Google Scholar
• Juárez Olguín H, Flores Pérez C, Ramírez Mendiola B, et al. Extemporaneous suspension of propafenone: attending lack of paediatric formulations in Mexico. Pediatr Cardiol 2008;29:1077–81
   PubMed Web of Science ®Google Scholar
• U.S. Pharmacopeial Convention, Inc. 59054 Uniformity of Dosage Units. 12601 Twinbrook Parkway, Rockville, MD; 2013:20852, 431–4
   Google Scholar
• Food and Drug Administration. Guidance for industry. Tablet scoring: nomenclature, labeling and data for evaluation; 2013. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM 269921.pdf [last accessed 14 Apr 2013]
   Google Scholar
• Thomson SA, Tuleu C, Wong ICK, et al. Minitablets: newmodality to deliver medicines to preschool aged children. Paediatrics 2009;123:235–8
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for Industry, orally disintegrating tablets; 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070578.pdf [last accessed 14 Apr 2013]
   Google Scholar
• Dobetti L. Fast-melting tablets: developments and technologies. Pharm Tech 2000;12:32–42
   Google Scholar
• Fukui-Soubou M, Terashima H, Kawashima K, et al. Efficacy, safety, and palatability of RACTAB® formulation amlodipine orally disintegrating tablets. Drugs RD 2011;11:327–36
   PubMedGoogle Scholar
• Freedman S, Freedman SB, Adler M, Seshadri S. Oral Ondansetron for gastroenteritis in a pedatric emergency department. N Engl J Med 2006;354:1698–705
   PubMed Web of Science ®Google Scholar
• Cohen IT, Joffe D, Hummer K, Soluri A. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg 2005;101:59–63
   PubMed Web of Science ®Google Scholar
• Agarwal V, Kothari BH, Moe DV, Khankari RK. Drug delivery: fast dissolve systems. In: Swarbrick J, ed. Encyclopedia of pharmaceutical technology. 3rd ed, vol. 1. New York (NY): Informa Healthcare USA, Inc; 2006:1104–14
   Google Scholar
• Reddy LH, Ghosh BR. Fast dissolving drug delivery systems: a review of the literature. Ind J Pharm Sci 2002;64:331–6
   Google Scholar
• Aurora J, Pathak V. Oral disintegrating technologies: oral disintegrating dosage forms: an overview. Drug Del Tech 2005;5:50–4
   Google Scholar
• Hamilton EL, Luts EM. Advanced orally disintegrating tablets bring significant benefits to patients and product life cycle. Drug Del Tech 2005;5:34–7
   Google Scholar
• Habib W, Khankari R, Honts J. Fast dissolving drug delivery systems. Crit Rev Ther Drug Carr Syst 2000;17:61–72
   PubMed Web of Science ®Google Scholar
• Lies MC, Atherton AD, Copping NM. Freeze-dried dosage forms and methods for preparing same. 1993: US Patent 5,188,825
   Google Scholar
• Sreenivas SA. Orodispersible tablets: new – fangled drug delivery system – a review. Ind Pharm Educ Res 2005;39:177–81
   Google Scholar
• Sugihara M, Hidaka M, Saitou A. Discriminatory features of dosage form and package. Jpn J Hosp Pharm 1986;12:322–8
   Google Scholar
• Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) – a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm 2011;78:462–9
   PubMed Web of Science ®Google Scholar
• Roblegg E, Schrank S, Griesbacher M, et al. Use of the direct compression aid Ludiflash® for the preparation of pellets via wet extrusion/spheronization. Drug Dev Ind Pharm 2011;37:1231–43
   PubMed Web of Science ®Google Scholar
• Tan Q, Zhang L, Liu G, et al. Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: design rationale and evaluation. Drug Dev Ind Pharm 2013;39:1364–71
   PubMed Web of Science ®Google Scholar
• Klancke J. Dissolution testing of orally disintegrating tablets. Diss Tech 2003;10:6–8
   Google Scholar
• Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop J Pharm Res 2009;8:161–72
   Web of Science ®Google Scholar
• Frey P. Film strips and pharmaceuticals. Pharma Mfg Package Sourcer 2006;Winter:92–3
   Google Scholar
• Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: a new approach to oral drug delivery system. Int J Pharm Inv 2013;3:67–76
   PubMedGoogle Scholar
• Ntege PN, Cook A, Vhembo T, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One 2012;7:e36186
   Google Scholar
• Nasrin D, Larson CP, Sultana S, Khan TU. Acceptability of and adherence to dispersible zinc tablet in the treatment of acute childhood diarrhoea. J Health Popul Nutr 2005;23:215–21
   PubMed Web of Science ®Google Scholar
• European Pharmacopoiea, 3rd ed. Strasbourg: Council of Europe; 1999:1347; Suppl. 2000
   Google Scholar
• Higuchi T, Perrin J, Robinson J, Repta AJ. Carbonation of aqueous solutions with acid anhydrides. J Pharm Sci 1965;54:1273–6
   PubMed Web of Science ®Google Scholar
• Eichman JD, Robinson JR. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998;15:925–30
   PubMed Web of Science ®Google Scholar
• Ekenved G, Elofsson R, Solvell L. Bioavailability studies on a buffered acetylsalicylic acid preparation. Acta Pharm Suec 1975;12:323–32
   PubMedGoogle Scholar
• Mohrle R. Effervescent tablets. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical dosage forms, 2nd ed. New York: Marcel Dekker, Inc.; 1989:285–328
   Google Scholar
• Michele TM, Knorr B, Vadas EB, Reiss TF. Safety of chewable tablets for children. J Asthma 2002;39:391–403
   PubMed Web of Science ®Google Scholar
• Weidle PJ, Abrams EJ, Gvetadze R, et al. A simplified weight-based method for paediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J 2006;25:59–64
   PubMed Web of Science ®Google Scholar
• Avicel CE-15, Microcrystalline cellulose and guar gum. For superior sensory characteristics in chewable tablets. Available from: http://www.fmcbiopolymer.com/Portals/bio/Content/Docs/Neutraceuticals/Avicel%20CE-15.pdf [last accessed 15 Apr 2013]
   Google Scholar
• Siewert M, Dressman J, Brown C, Shah V. FIP/AAPS Guidelines for dissolution/in vitro release testing of novel/special dosage forms. Diss Tech 2003;10:February:6–15
   Google Scholar
• Committee on Human Medicinal Products CHMP reflection paper: formulation of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005. London: European Medicines Agency; 2006
   Google Scholar
• Lam HS, Chow CM, Poon WT, et al. Risk of vitamin a toxicity from candy-like chewable vitamin supplements for children. Paediatrics 2006;118:820–4
   PubMed Web of Science ®Google Scholar
• Reiland TL, Lipari JM. Flavors and flavor modifiers. In: Swarbrick J, ed. Encyclopedia of pharmaceutical technology. 3rd ed. New York (NY): Informa Healthcare USA, Inc.; 2007:1763–72
   Google Scholar
• Schoneker DR. Coloring agents for use in pharmaceuticals. In: Swarbrick J, ed. Encyclopedia of pharmaceutical technology. 3rd ed. New York (NY): Informa Healthcare USA, Inc.; 2007:648–70
   Google Scholar
• Food and Drug Administration. Code of Federal Regulations, Title 21, Parts 70–82 for colourants; 1938
   Google Scholar
• Cooper JA. Question of taste: uses of sucrose. Manuf Chem 2003;74:71–2,74
   Google Scholar
• Parasrampuria J, Pitt SW. Liquid oral preparations. In: Swarbrick J, ed. Encyclopedia of pharmaceutical technology. 3rd ed. New York (NY): Informa Healthcare USA, Inc.; 2007:2216–30
   Google Scholar
• Lachman L. The instability of antimicrobial preservatives. Bull Parent Drug Assoc 1968;22:127–44
   PubMedGoogle Scholar
• Patel NK, Kostenbauder HD. Interaction of preservatives with macromolecules. I. Binding of parahydroxybenzoic acid esters by polyoxyethylene 20 sorbitan monooleate (tween 80). J Am Pharm Assoc Sci Ed 1958;47:289–93
   Google Scholar
• Morefield EM, Feldkamp JR, Peck GE, et al. Reformulation information for suspensions. Int J Pharm 1987;34:263–5
   Web of Science ®Google Scholar
• Wotton PK, Khosla R. Acceptability of excipients in the European community and USA. BIRA J 1991;10:11–13
   Google Scholar
• Food and Drug Administration. Toxicological principles for the safety of food ingredients: Redbook. Washington, DC: U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition; 2000
   Google Scholar
• Macdonald MG, Getson PR, Glasgow AM, et al. Propylene glycol: increased incidence of seizures in low birth weight infants. Paediatrics 1987;79:622–5
   PubMed Web of Science ®Google Scholar
• Glasgow AM, Boeckx RI, Miller MK, et al. Hyperosmolarity in small infants due to propylene glycol. Paediatrics 1983;72:353–5
   PubMed Web of Science ®Google Scholar
• Gershanik JJ, Boecler B, George W, et al. The gasping syndrome: benzyl alcohol (BA) poisoning? Clin Res 1981;29:895A
   Google Scholar
• Benda GI, Hiller JI, Reynolds. JW. Benzyl alcohol toxicity: impact on neurological handicaps among surviving very low birth weight infants. Paediatrics 1986;77:500–6
   PubMed Web of Science ®Google Scholar
• Warner CR, Diachenko GW. Bailey CJ. Sulfites: an important food safety issue. Food Testing & Analysis; 2000. Available from: www.cfsan.fda.gov/~dms/fssulfit.html [last accessed 3 May 2013]
   Google Scholar
• Reinke CM, Breitkreutz J, Leuenberger H. Aluminium in over-the-counter drugs – risks outweigh benefits? Drug Saf 2003;26:1011–25
   PubMed Web of Science ®Google Scholar
• Hartauer KJ, Arbuthnot GN, Baertschi SW, et al. Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product. Pharm Dev Technol 2000;5:303–10
   PubMed Web of Science ®Google Scholar
• Wirth DD, Baertschi SW, Johnson RA, et al. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci 1998;87:31–9
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Cook WG, Fenton ME. Handbook of pharmaceutical excipients. 7th ed. London: Philadelphia; 2012
   Google Scholar
• FAO/WHO. Evaluation of certain food additives and contaminants. Twenty-seventh report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep, Ser No 696. [124 FAO/WHO, Toxicological evaluation of certain food additives with a review of general principles and of specifications, Seventeenth report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep 1974; Ser. No. 539; 1983
   Google Scholar
• FAO/WHO. Expert committee on food additives. Specification for the identity and purity and toxicological evaluation of food colors. WHO Food Add 1966;66:25, FAO Nutr Mtgs Rep. Ser No 38B
   Google Scholar
• FAO/WHO. Evaluation of certain food additives and contaminants. Twenty-fifth report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep, Ser. No. 669; 1981
   Google Scholar
• FAO/WHO. Evaluation of certain food additives and contaminants. Twenty-eighth report of the FAO/WHO expert committee on food additives. World Health Organ Tech Rep, Ser No 710; 1984
   Google Scholar
• FAO/WHO. Evaluation of certain food additives and contaminants. Thirty-fifth report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep, Ser No 789; 1990
   Google Scholar
• Smith DV, Margolskee RF. Making sense of taste. Sci Am 2001;284:34
   PubMedGoogle Scholar
• Smith DV, Margolskee RF. Making sense of taste. Sci Am 2001;284:36
   PubMedGoogle Scholar
• Stier R. Masking bitter taste of pharmaceutical actives. Drug Del Tech 2004;2:52–7
   Google Scholar
• Schiffman HS. Sensation and perception: an integrated approach. 5th ed. Ontario, Canada: John Wiley and Sons; 2000:163–9
   Google Scholar
• Schiffman SS. Critical illness and changes in sensory perception. Proc Nutr Soc 2007;66:331–45
   PubMed Web of Science ®Google Scholar
• Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Safety 2008;31:199–215
   PubMed Web of Science ®Google Scholar
• James CE, Laing, DG, Oram N. A comparison of the ability of 8–9-year-old children and adults to detect taste stimuli. Physiol Behav 1997;62:193–7
   PubMed Web of Science ®Google Scholar
• James CE, Laing DG, Oram N, Hutchinson I. Perception of sweetness in simple and complex taste stimuli by adults and children. Chem Senses 1999;24:281–7
   PubMed Web of Science ®Google Scholar
• Mennella JA, Pepino MY, Reed DR. Genetic and environmental determinants of bitter perception and sweet preferences. Paediatrics 2005;115:216–22
   PubMed Web of Science ®Google Scholar
• EMEA. (2008). Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Available from: http://ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf [last accessed 14 Apr 2013]
   Google Scholar
• Davies HE, Tuleu C. Medicines for children: a matter of taste. J Pediatr 2008;153:599–604
   PubMed Web of Science ®Google Scholar
• Funasaki N, Uratsuji I. Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. Chem Pharm Bull 2006;54:1155–61
   PubMed Web of Science ®Google Scholar
• Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Exp Opin Drug Deliv 2007;4:417–26
   PubMed Web of Science ®Google Scholar
• Madgulkar AR, Bhalekar MR, Patel KG, et al. Comparative evaluation of taste masking methods for fexofenadine HCl. Pharm Rev 2007;Oct–Nov:176–80
   Google Scholar
• Ndesendo VMK, Meixner W. Microencapsulation of chloroquine diphosphate by Eudragit RS.100. J Microencap 1996;13:1–8
   PubMed Web of Science ®Google Scholar
• Sjoquist R, Graffner C, Ekman I, et al. In vivo validation of the release rate and palatability of remoxipride-modified release suspension. Pharm Res 1993;10:1020–6
   PubMed Web of Science ®Google Scholar
• Bruschi DL, Giovanni ML, Leonardo R, Luigi B. Inventors and assignee European patent, EP1534251; 2004
   Google Scholar
• Stevenson RJ. Confusing tastes and smells: how odours can influence the perception of sweet and sour tastes. Chem Senses 1999;24:627–35
   PubMed Web of Science ®Google Scholar
• Breslin PA, Beauchamp GK. Salt enhances flavour by suppressing bitterness. Nature 1997;387:563
   PubMed Web of Science ®Google Scholar
• Keast RS, Breslin PA. Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts. Pharm Res 2002;19:1019–26
   PubMed Web of Science ®Google Scholar
• Keast RS, Breslin, PS. Bitterness suppression with zinc sulfate and Na-cyclamate: a model of combined peripheral and central neural approaches to flavor modification. Pharm Res 2005;22:1970–7
   PubMed Web of Science ®Google Scholar
• Hussain MM, Barcelon SA. Inventors; Warner-Lambert Company, assignee. Flavor enhancing and medicinal taste masking agent. Unites States patent 4,983,394; 1991
   Google Scholar
• Fuisz RC. Inventors; Fuisz Pharmaceutical Ltd, assignee. Taste masking of pharmaceutical floss with phenol. Unites States patent 5,028,632; 1991
   Google Scholar
• Fu Y, Yang S, Jeong SH, et al. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carr Syst 2004;21:433–75
   PubMed Web of Science ®Google Scholar
• Cano J, Mintijano H, Lopez-Cremades F, Borrego F. Masking the bitter taste of pharmaceuticals. Manuf Chem 2000;71:16–17
   Google Scholar
• U.S. Food and Drug Administration. Toxicological principles for the safety assessment of direct food additives and color additives used in foods. Office of Food Additive Safety, HFS-200, Center for Food Safety and Applied Nutrition Food and Drug Administration. College Park (MD): Red Book; 1982
   Google Scholar
• Bhardwaj S, Hayward M. Inventors; SmithKline Beecham Corporation, assignee. Palatable pharmaceutical compositions. Unites States patent 5,578,316; 1996
   Google Scholar
• Danny YU. Inventor; Johnson and Johnson, assignee. Taste masked pharmaceutical liquid formulations. PCT Int. Appl. WO 01/03698; 2001
   Google Scholar
• Iton A, Niwa T. Inventors; Pfizer Inc., Assignee. Rapidly releasing and taste masking pharmaceutical dosage form. United States patent 6,221,402; 2001
   Google Scholar
• Alkire TG, Sanftleben RA, Schuehle SS. Inventors; Cima Labs, assignee. Taste masking microparticles for oral dosage forms. United States patent 5,607,697; 1997
   Google Scholar
• Mauger JW, Robinson DH. Inventors; University of Nebraska, assignee. Coating technology for taste masking orally administered bitter drugs. United States patent 5,728,403; 1998
   Google Scholar
• Wurster DE. Particle coating method. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical dosage form. New York: Marcel Dekker Inc.; 1981:119
   Google Scholar
• Chiappetta DA, Carcaboso AM, Bregni C, et al. Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous paediatric anti-HIV/AIDS liquid formulations with improved patient compliance. AAPS PharmSciTech 2009;10:1–6
   PubMed Web of Science ®Google Scholar
• Leonard GS, Cooper D. Inventors; Smithkline Beecham Plc, assignee. Oral liquid compositions containing paroxetine resinate. United States patent 5,811,436; 1998
   Google Scholar
• Douglas SJ, Bird FR. Inventors; Glaxo Group, assignee. Drug adsorbates. United States patent 5,032,393; 1991
   Google Scholar
• Hughes L. Selecting the right ion exchange resin. Pharma Qual 2005;1:54–6
   Google Scholar
• Prasad N, Straus D, Reichart G. Cyclodextrin flavor delivery systems. US Patent 6,287,603; 1999
   Google Scholar
• Kaartama R, Turunen E, Toljamo K, et al. The effect of hydroxypropyl-beta-cyclodextrin and sucrose on the sublingual absorption of midazolam in rabbits. Eur J Pharm Biopharm 2012;81:178–83
   PubMed Web of Science ®Google Scholar
• Freudenberg K, Cramer F, Plieninger H. Inclusion compounds of physiologically active organic compounds. German patent 895769; 1953
   Google Scholar
• Lv HX, Zhang ZH, Jiang H, et al. Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex. Pharmazie 2012;67:46–53
   PubMed Web of Science ®Google Scholar
• Alpha MOS, sensory expert and analytical instruments. Avenue Didier Daurat, 31400 Toulouse – France. Available from: http://www.alpha-mos.com/en/technology/tecprinciple.php [last accessed 20 Sept 2013]
   Google Scholar
• Choi DH, Kim NA, Nam TS, et al. Evaluation of taste-masking effects of pharmaceutical sweeteners with an electronic tongue system. Drug Dev Ind Pharm 2013. [Epub ahead of print]. doi: 10.3109/03639045.2012.758636
   Google Scholar